The BARI 2D study: A randomised trial of therapies for type 2 diabetes and coronary artery disease

Diabetes and Vascular Disease Research

Volumn 7, Issue 1, 2010, Pages 69-72

  Rutter, Martin K ^a,b,e   Nesto, Richard W ^c,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Cardiovascular Research Group   (United Kingdom)

Author keywords

Coronary artery disease; Insulin; Revascularisation; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; WEIGHT GAIN;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 77949409023     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109354145     Document Type: Short Survey

References (9)

1. Frye RL, August P, Brooks MM, et al. (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360: 2503-2515
2. Boden WE, O'Rourke RA, Teo KK, et al. (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356: 1503-1516
3. Pepine CJ, Bourassa MG, Chaitman BR, et al. (1999) Factors influencing clinical outcomes after revascularization in the asymptomatic cardiac ischemia pilot (ACIP). ACIP Study Group. J Card Surg 14: 1-8.
4. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants (1997) Lancet 350: 461-468
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591
6. Skyler JS, Bergenstal R, Bonow RO, et al. (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53: 298-304.
7. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA (2009) ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 119: 1330-1352
8. Stettler C, Wandel S, Allemann S, et al. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370: 937-948
9. Home PD, Pocock SJ, Beck-Nielsen H, et al. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125-2135